BC089597 Inhibitors
Chemical inhibitors of BC089597 include a variety of compounds that can affect the protein's activity by different mechanisms. Palbociclib, a selective inhibitor of CDK4 and CDK6, can lead to reduced activity of BC089597 through cell cycle arrest at the G1 phase. This suggests that BC089597 activity is tied to the cell cycle progression regulated by these kinases. Similarly, Trametinib and Cobimetinib, both MEK inhibitors, can impede the phosphorylation and activation of ERK in the MAPK pathway, potentially leading to a decrease in BC089597 activity if it is part of this signaling cascade. Crizotinib, which targets ALK and ROS1, can also decrease BC089597 activity by inhibiting the kinases that may act upstream of the protein.
Additionally, Olaparib, a PARP inhibitor, can lead to the functional impairment of BC089597 if it is involved in DNA repair pathways, suggesting a role for BC089597 in the maintenance of genomic integrity. Erlotinib's inhibition of EGFR can reduce the activity of BC089597 if it is involved in the EGFR signaling network, while Venetoclax, a BCL-2 inhibitor, can affect BC089597 if it is connected to cell survival pathways mediated by BCL-2. Dasatinib's role as an inhibitor of Src family kinases and ABL suggests that BC089597 activity can be decreased by inhibiting kinases in these families. Bortezomib can lead to an accumulation of misfolded BC089597 proteins by inhibiting the proteasome, which suggests that proper folding and degradation are crucial for BC089597's activity. Lastly, Sorafenib and Sunitinib, which inhibit multiple kinases including RAF, VEGFR, and PDGFR, can inhibit BC089597 activity by targeting signaling pathways that involve these kinases, while Lapatinib's inhibition of EGFR and HER2 suggests a similar mechanism of action on BC089597 if it acts downstream of these receptors.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. BC089597 has been implicated in cell cycle regulation, and inhibition of CDK4/6 by Palbociclib could lead to reduced activity of BC089597 through cell cycle arrest in the G1 phase. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a PARP inhibitor. Since PARP is involved in DNA repair, its inhibition can result in synthetic lethality in cells with BRCA mutations. If BC089597 is involved in DNA repair pathways, Olaparib inhibition of PARP could result in the functional impairment of BC089597. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that prevents the phosphorylation and activation of ERK, which is downstream in the MAPK pathway. Inhibition of MEK/ERK signaling by Trametinib could result in the functional inhibition of BC089597 if it is part of this signaling cascade. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. By inhibiting EGFR, Erlotinib could reduce the activity of BC089597 if the protein is part of the EGFR signaling network that regulates cell proliferation and survival. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax is a BCL-2 inhibitor. By inhibiting BCL-2, an anti-apoptotic protein, Venetoclax can lead to apoptotic cell death. If BC089597 functions to promote cell survival via the BCL-2 pathway, its activity would be functionally inhibited by Venetoclax. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase and ABL inhibitor. If BC089597 is active downstream of Src or ABL kinases, Dasatinib's inhibition of these kinases could result in decreased BC089597 activity by preventing activation through phosphorylation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If BC089597 is regulated by proteasomal degradation, inhibition of the proteasome by Bortezomib could result in the accumulation of misfolded BC089597 proteins, thereby inhibiting its functional activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor that also targets VEGFR and PDGFR. If BC089597 is part of the RAF/MEK/ERK pathway, Sorafenib's inhibition of RAF could lead to functional inhibition of BC089597 by blocking the signaling cascade. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is an inhibitor of multiple receptor tyrosine kinases, including VEGFR and PDGFR. If BC089597 is involved in pathways downstream of these kinases, Sunitinib could inhibit the functional activity of BC089597 by inhibiting these signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2. If BC089597 acts downstream of EGFR or HER2, Lapatinib's inhibition of these receptors could lead to the functional inhibition of BC089597 by impeding the signaling through these pathways. | ||||||